
Laurus Labs Ltd
NSE:LAURUSLABS

Laurus Labs Ltd?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
419.85
829.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Laurus Labs Ltd hold over its rivals?
What risks and challenges
does Laurus Labs Ltd face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Laurus Labs Ltd.
Provide an overview of the primary business activities
of Laurus Labs Ltd.
What unique competitive advantages
does Laurus Labs Ltd hold over its rivals?
What risks and challenges
does Laurus Labs Ltd face in the near future?
Has there been any significant insider trading activity
in Laurus Labs Ltd recently?
Summarize the latest earnings call
of Laurus Labs Ltd.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Laurus Labs Ltd.
Provide P/S
for Laurus Labs Ltd.
Provide P/E
for Laurus Labs Ltd.
Provide P/OCF
for Laurus Labs Ltd.
Provide P/FCFE
for Laurus Labs Ltd.
Provide P/B
for Laurus Labs Ltd.
Provide EV/S
for Laurus Labs Ltd.
Provide EV/GP
for Laurus Labs Ltd.
Provide EV/EBITDA
for Laurus Labs Ltd.
Provide EV/EBIT
for Laurus Labs Ltd.
Provide EV/OCF
for Laurus Labs Ltd.
Provide EV/FCFF
for Laurus Labs Ltd.
Provide EV/IC
for Laurus Labs Ltd.
Show me price targets
for Laurus Labs Ltd made by professional analysts.
What are the Revenue projections
for Laurus Labs Ltd?
How accurate were the past Revenue estimates
for Laurus Labs Ltd?
What are the Net Income projections
for Laurus Labs Ltd?
How accurate were the past Net Income estimates
for Laurus Labs Ltd?
What are the EPS projections
for Laurus Labs Ltd?
How accurate were the past EPS estimates
for Laurus Labs Ltd?
What are the EBIT projections
for Laurus Labs Ltd?
How accurate were the past EBIT estimates
for Laurus Labs Ltd?
Compare the revenue forecasts
for Laurus Labs Ltd with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Laurus Labs Ltd and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Laurus Labs Ltd against its competitors.
Analyze the profit margins
(gross, operating, and net) of Laurus Labs Ltd compared to its peers.
Compare the P/E ratios
of Laurus Labs Ltd against its peers.
Discuss the investment returns and shareholder value creation
comparing Laurus Labs Ltd with its peers.
Analyze the financial leverage
of Laurus Labs Ltd compared to its main competitors.
Show all profitability ratios
for Laurus Labs Ltd.
Provide ROE
for Laurus Labs Ltd.
Provide ROA
for Laurus Labs Ltd.
Provide ROIC
for Laurus Labs Ltd.
Provide ROCE
for Laurus Labs Ltd.
Provide Gross Margin
for Laurus Labs Ltd.
Provide Operating Margin
for Laurus Labs Ltd.
Provide Net Margin
for Laurus Labs Ltd.
Provide FCF Margin
for Laurus Labs Ltd.
Show all solvency ratios
for Laurus Labs Ltd.
Provide D/E Ratio
for Laurus Labs Ltd.
Provide D/A Ratio
for Laurus Labs Ltd.
Provide Interest Coverage Ratio
for Laurus Labs Ltd.
Provide Altman Z-Score Ratio
for Laurus Labs Ltd.
Provide Quick Ratio
for Laurus Labs Ltd.
Provide Current Ratio
for Laurus Labs Ltd.
Provide Cash Ratio
for Laurus Labs Ltd.
What is the historical Revenue growth
over the last 5 years for Laurus Labs Ltd?
What is the historical Net Income growth
over the last 5 years for Laurus Labs Ltd?
What is the current Free Cash Flow
of Laurus Labs Ltd?
Discuss the annual earnings per share (EPS)
trend over the past five years for Laurus Labs Ltd.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
IN |
![]() |
Laurus Labs Ltd
NSE:LAURUSLABS
|
446.5B INR | 44.6 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
765.6B USD | 37 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
403.3B USD | 13.6 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK | 13.3 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
207.3B CHF | 9.4 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
180.2B CHF | 10.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
167.5B GBP | 131.2 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
213.1B USD | 9 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD | 292.4 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
141B USD | 7.6 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
IN |
![]() |
Laurus Labs Ltd
NSE:LAURUSLABS
|
Average EV/EBITDA:
401.3
44.6
|
26%
|
1.7 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
37
|
30%
|
1.2 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
13.6
|
7%
|
1.9 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
13.3
|
13%
|
1 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
9.4
|
5%
|
1.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
10.1
|
5%
|
2 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
131.2
|
10%
|
13.1 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
9
|
8%
|
1.1 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
292.4
|
N/A | N/A |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
7.6
|
2%
|
3.8 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.